Evidence map›Paper›PMID 36671530›Full record

ArticleBiomolecules2023

Relationship between 4-Hydroxynonenal (4-HNE) as Systemic Biomarker of Lipid Peroxidation and Metabolomic Profiling of Patients with Prostate Cancer.

Matea Nikolac Perkovic, Morana Jaganjac, Lidija Milkovic, Tea Horvat, David Rojo, Kamelija Zarkovic, Marijana Ćorić, Tvrtko Hudolin, Georg Waeg, Biserka Orehovec and 1 more

Abstract read
In one paragraph

Article in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matea Nikolac PerkovicDivision of Molecular Medicine, Ruder Boskovic Institute, HR-10000 Zagreb, Croatia.ORCID 0000-0002-3113-0778
Morana JaganjacDivision of Molecular Medicine, Ruder Boskovic Institute, HR-10000 Zagreb, Croatia.ORCID 0000-0001-5051-1843
Lidija MilkovicDivision of Molecular Medicine, Ruder Boskovic Institute, HR-10000 Zagreb, Croatia.ORCID 0000-0002-4484-039X
Tea HorvatDivision of Molecular Medicine, Ruder Boskovic Institute, HR-10000 Zagreb, Croatia.
David RojoCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad CEU San Pablo, Campus Montepríncipe, ES-28003 Madrid, Spain.
Kamelija ZarkovicDivision of Pathology, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Kispaticeva 12, HR-10000 Zagreb, Croatia.
Marijana ĆorićDivision of Pathology, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Kispaticeva 12, HR-10000 Zagreb, Croatia.
Tvrtko HudolinDivision of Urology, School of Medicine, University of Zagreb, University Hospital Centre Zagreb, Kispaticeva 12, HR-10000 Zagreb, Croatia.ORCID 0000-0002-6658-2344
Georg WaegInstitute of Molecular Biosciences, Karl Franzens University, A-8010 Graz, Austria.
Biserka OrehovecClinical Hospital Dubrava, HR-10000 Zagreb, Croatia.
Neven ZarkovicDivision of Molecular Medicine, Ruder Boskovic Institute, HR-10000 Zagreb, Croatia.ORCID 0000-0001-5032-0369

Funding

MINGO, Croatia CRO_A-00033
6 · The paper itself

Abstract

An oxidative degradation product of the polyunsaturated fatty acids, 4-hydroxynonenal (4-HNE), is of particular interest in cancer research due to its concentration-dependent pleiotropic activities affecting cellular antioxidants, metabolism, and growth control. Although an increase in oxidative stress and lipid peroxidation was already associated with prostate cancer progression a few decades ago, the knowledge of the involvement of 4-HNE in prostate cancer tumorigenesis is limited. This study investigated the appearance of 4-HNE-protein adducts in prostate cancer tissue by immunohistochemistry using a genuine 4-HNE monoclonal antibody. Plasma samples of the same patients and samples of the healthy controls were also analyzed for the presence of 4-HNE-protein adducts, followed by metabolic profiling using LC-ESI-QTOF-MS and GC-EI-Q-MS. Finally, the analysis of the metabolic pathways affected by 4-HNE was performed. The obtained results revealed the absence of 4-HNE-protein adducts in prostate carcinoma tissue but increased 4-HNE-protein levels in the plasma of these patients. Metabolomics revealed a positive association of different long-chain and medium-chain fatty acids with the presence of prostate cancer. Furthermore, while linoleic acid positively correlated with the levels of 4-HNE-protein adducts in the blood of healthy men, no correlation was obtained for cancer patients indicating altered lipid metabolism in this case. The metabolic pathway of unsaturated fatty acids biosynthesis emerged as significantly affected by 4-HNE. Overall, this is the first study linking 4-HNE adduction to plasma proteins with specific alterations in the plasma metabolome of prostate cancer patients. This study revealed that increased 4-HNE plasma protein adducts could modulate the unsaturated fatty acids biosynthesis pathway. It is yet to be determined if this is a direct result of 4-HNE or whether they are produced by the same underlying mechanisms. Further mechanistic studies are needed to grasp the biological significance of the observed changes in prostate cancer tumorigenesis.

Indexed as

AldehydesProstatic NeoplasmsBiomarkersCarcinogenesisFatty Acids, UnsaturatedHumansLipid PeroxidationMaleProteins4-hydroxy-2-nonenalAldehydesBiomarkersFatty Acids, UnsaturatedProteins4-hydroynonenal (4-HNE)cancerGS-MSLC-MSlipid peroxidationmetabolomicsprostate carcinoma

Identifiers

PMID36671530
PMCPMC9855859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.